SRC and Cholecystitis: As for multi-target inhibitors, Ilorasertib (ABT-348) targeting Aurora kinase A/B, VEGFR/PDGFR and Src family, and ENMD-2076 targeting Aurora kinase A, VEGFR2/FGFR/Flt-3/c-Kit, were found to cause more DLTs, such as pancreatic disease and hypertension, fatigue, cholecystitis, and QTc prolonged [19, 20].